B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jade Biosciences, Inc. - Common Stock (NQ:JBIO)

16.92 -0.82 (-4.62%)
Streaming Delayed Price Updated: 3:38 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jade Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Jade Biosciences Announces Pricing of Public Offering of Common Stock
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces Proposed Underwritten Public Offering
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials ↗
Jade Biosciences (NASDAQ:JBIO) said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company’s plan to advance the... 
Via MarketBeat
News headline image
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces $45 Million Private Placement
From Jade Biosciences
Via GlobeNewswire
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Announces $135 Million Private Placement
From Jade Biosciences
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
News headline image
Jade Biosciences Posts Wider Loss in Q2 ↗
Via The Motley Fool
News headline image
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.